Selective antimicrobial activity of cell lytic enzymes in a bacterial consortium
The role that the complex microbial communities play in human and environmental health cannot be understated. The increased information about community complexity, as well as the overuse of broad-spectrum antibiotics, suggest that new approaches to target specific organisms within a community context are essential towards new antimicrobial therapies. Here, we have assessed the activity and selectivity of two cell wall lytic enzymes, lysostaphin (Lst) and PlyPH, in the presence of multiple bacteria and under varied media conditions. Lst and PlyPH target the clinically relevant pathogens Staphylococcus aureus and Bacillus cereus, respectively. Lst was effective under all conditions resulting in ~ 4-log and ~ 3-log reduction at 100 μg/mL in actively growing monoculture and co-culture, respectively. PlyPH was also selective but less active and more susceptible to media and cell population changes. Lst and PlyPH activities could be increased in supernatants from actively growing cultures in the presence of a protease inhibitor cocktail, suggesting a possible role played by proteases secreted during cell growth in reducing lytic enzyme activity. This work demonstrates the utility of cell wall lytic enzymes for targeted pathogen killing or microbial community remodeling.
KeywordsLysostaphin PlyPH Selective antimicrobial activity Microbial community Skin microbiome Cell lytic enzymes
This study was financially supported by the Global Research Laboratory Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (2014K1A1A2043032), and Colgate-Palmolive Company.
Compliance with ethical standards
This work does not contain any studies with humans or animals performed by any of the authors.
Conflict of interest
The authors declare that they have no conflict of interest.
- Christensen GD, Simpson WA, Bisno AL, Beachey EH (1982) Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun 37:318–326Google Scholar
- Gilmer DB, Schmitz JE, Euler CW, Fischetti VA (2013) Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:2743–2750. https://doi.org/10.1128/AAC.02526-12 CrossRefGoogle Scholar
- Johnson CT, Wroe JA, Agarwal R, Martin KE, Guldberg RE, Donlan RM, Westblade LF, García AJ (2018) Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by Staphylococcus aureus and supports fracture healing. Proc Natl Acad Sci USA 115:E4960–E4969. https://doi.org/10.1073/pnas.1801013115 CrossRefGoogle Scholar
- Miao J, Pangule RC, Paskaleva EE, Hwang EE, Kane RS, Linhardt RJ, Dordick JS (2011) Lysostaphin-functionalized cellulose fibers with anti-staphylococcal activity for wound healing applications. Biomaterials 32:9557–9567. https://doi.org/10.1016/j.biomaterials.2011.08.080 CrossRefGoogle Scholar
- O’Toole GA (2011) Microtiter dish biofilm formation assay. J Vis Exp:10–11. https://doi.org/10.3791/2437
- Paskaleva EE, Mundra RV, Mehta KK, Pangule RC, Wu X, Glatfelter WS, Chen Z, Dordick JS, Kane RS (2015) Binding domains of Bacillus anthracis phage endolysins recognize cell culture age-related features on the bacterial surface. Biotechnol Prog 31:1487–1493. https://doi.org/10.1002/btpr.2172 CrossRefGoogle Scholar
- Rudin L, Sjöström JE, Lindberg M, Philipson L (1974) Factors affecting competence for transformation in Staphylococcus aureus. J Bacteriol 118:155–164Google Scholar
- Satishkumar RS, Vertegel AA (2011) Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro. Nanotechnology 22:505103. https://doi.org/10.1088/0957-4484/22/50/505103/pdf CrossRefGoogle Scholar
- Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47:1301–1307. https://doi.org/10.1128/AAC.47.4.1301-1307.2003 CrossRefGoogle Scholar
- Wu X, Kwon S-J, Kim J, Kane RS, Dordick JS (2017) Biocatalytic nanocomposites for combating bacterial pathogens. Annu Rev Chem Biomol Eng 8:87–113. https://doi.org/10.1146/annurev-chembioeng-060816-101612 CrossRefGoogle Scholar